Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

New England Journal of Medicine

Volumn 366, Issue 6, 2012, Pages 520-529

  Baselga, José ^a   Campone, Mario ^b   Piccart, Martine ^c   Burris III, Howard A ^d   Rugo, Hope S ^e   Sahmoud, Tarek ^f   Noguchi, Shinzaburo ^g   Gnant, Michael ^h   Pritchard, Kathleen I ⁱ   Lebrun, Fabienne ^c   Beck, J Thaddeus ^j   Ito, Yoshinori ^k   Yardley, Denise ^d   Deleu, Ines ^l   Perez, Alejandra ^m   Bachelot, Thomas ⁿ   Vittori, Luc ^f   Xu, Zhiying ^f   Mukhopadhyay, Pabak ^f   Lebwohl, David ^f   Hortobagyi, Gabriel N ^o   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b Institut de cancerologie de l'Ouest Rene Gauducheau   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g OSAKA UNIVERSITY   (Japan)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j Highlands Oncology Group   (United States)

^k CANCER INSTITUTE HOSPITAL   (Japan)

^l Oncology Center   (Belgium)

^m Memorial Cancer Institute   (United States)

ⁿ CENTRE LÉON BÉRARD   (France)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VISCERAL METASTASIS; VOMITING; WEIGHT REDUCTION;

EID: 84863078767     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1109653     Document Type: Article

References (23)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42. (Pubitemid 36682823)
2. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606. [Erratum, J Clin Oncol 2001;19:3302.] (Pubitemid 32451796)
3. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-67.
4. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
5. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98:1285-91. (Pubitemid 44530724)
6. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptorpositive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70.
7. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600. [Erratum, J Clin Oncol 2011;29:2293.]
8. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-87.
9. Burstein HJ. Novel agents and future directions for refractory breast cancer. Semin Oncol 2011;38:Suppl 2:S17-S24.
10. Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12:1061S-1068S. (Pubitemid 43259844)
11. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Crosstalk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-336S. (Pubitemid 38116639)
12. Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010;584:124-8.
13. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009;284:6361-9.
14. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010;22:169-76.
15. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28. (Pubitemid 41003721)
16. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
18. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), version 3.0. Bethesda, MD: Cancer Therapy Evaluation Program, August 9, 2006 (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf).
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
20. Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
21. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
22. Chow LWC, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.
23. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.